• J Opioid Manag · Mar 2009

    Multicenter Study Clinical Trial

    Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain.

    • Mark Wallace, Dwight E Moulin, Richard L Rauck, Sarita Khanna, Iulia Cristina Tudor, Roman Skowronski, and John Thipphawong.
    • San Diego Medical Center, University of California, La Jolla, California, USA.
    • J Opioid Manag. 2009 Mar 1;5(2):97-105.

    ObjectiveTo assess the safety and efficacy of long-term repeated dosing of OROS hydromorphone in chronic pain patients.DesignThis multicenter, open-label extension trial enrolled patients from three short-term OROS hydromorphone trials.SettingFifty-six centers in the United States and Canada.PatientsAdults with chronic cancer pain or chronic nonmalignant pain who were receiving stable doses of OROS hydromorphone (> or = 8 mg/day). Three hundred and eighty-eight patients were enrolled, 106 patients completed at least 12 months of therapy.InterventionsOROS hydromorphone (individualized doses) was administered once daily.Main Outcome MeasuresSafety and efficacy (Brief Pain Inventory and patient and investigator global evaluations) were assessed at monthly visits.ResultsThe median duration of extended OROS hydromorphone therapy was 274 days. The median daily dose of study medication was 32.0 mg at extension-study baseline, 40.0 mg at month 3, and 48.0 mg at months 6, 9, and 12, respectively. The most frequently reported adverse events were nausea (n = 93, 24.0 percent) and constipation (n = 75, 19.3 percent). The analgesic effects of OROS hydromorphone, assessed using the Brief Pain Inventory, were maintained throughout the extension. At 12 months, 72.4 percent of patients and 75.9 percent of investigators rated overall treatment as good, very good, or excellent.ConclusionsOnce-daily OROS hydromorphone is an osmotically driven, controlled-release preparation that may be particularly well suited to long-term use, because it provides consistent plasma concentrations and sustained around-the-clock analgesia. In this study, the benefits of OROS hydromorphone attained in short-term studies were maintained in the long-term when daily administration was continued.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…